Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  SenzaGen AB    SENZA   SE0010219626

SENZAGEN AB

(SENZA)
  Report
End-of-day quote. End-of-day quote NASDAQ OMX STOCKHOLM - 10/21
20.6 SEK   -5.07%
09/16SENZAGEN : Global medical device company places SEK 0.6 million order
AQ
09/11SENZAGEN : receives order for GARD™skin and GARD™potency from a major US chemical company
AQ
SummaryChartsNewsCompanyFinancials 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

SenzaGen : receives order for GARD™skin and GARD™potency from a major US chemical company

share with twitter share with LinkedIn share with facebook
09/11/2020 | 02:31am EDT

SenzaGen will assess the skin sensitizing hazards of chemicals for a global chemical company based in the US. The new order, with a value of approximately SEK 0.4 million, includes testing with both GARD™skin and GARD™potency. The unique ability of the GARD technology to assess formulations and determine whether a substance is a weak or strong allergen without animal testing, was key for the order. The tests will be carried out at SenzaGen's laboratory in Lund, Sweden.

With an industry-leading product and technology pipeline, the customer is headquartered in the US and operates globally. Connected to one of the customer’s investigatory projects, this new order follows a successful evaluation of the GARD tests earlier this year.

“I am very pleased about this collaboration and we are looking forward to supporting their safety testing needs now and in the future. The chemical industry as a whole has a great need for safety testing and this project is in line with the customer’s commitment to the 3Rs – reduce, refine and replace animals in toxicology testing. It is with global customer references like this that we build credibility and lay the foundation for future growth”, says Axel Sjöblad, CEO of SenzaGen.

SenzaGen’s test platform GARD provides a highly accurate in vitro method for skin sensitization assessment of chemicals, including formulations, traditionally considered “difficult-to-test” samples. The method targets companies looking to optimize their testing strategy, thus increasing the safety of products while avoiding animal testing.

© Modular Finance, source Nordic Press Releases


share with twitter share with LinkedIn share with facebook
All news about SENZAGEN AB
09/16SENZAGEN : Global medical device company places SEK 0.6 million order
AQ
09/11SENZAGEN : receives order for GARD™skin and GARD™potency from a majo..
AQ
More news
Financials
Sales 2019 4,92 M 0,56 M 0,56 M
Net income 2019 -50,2 M -5,73 M -5,73 M
Net cash 2019 120 M 13,7 M 13,7 M
P/E ratio 2019 -6,00x
Yield 2019 -
Capitalization 429 M 49,0 M 48,9 M
EV / Sales 2018 47,0x
EV / Sales 2019 56,6x
Nbr of Employees 17
Free-Float 84,2%
Chart SENZAGEN AB
Duration : Period :
SenzaGen AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Axel Sjöblad Chief Executive Officer
Karl Arne Krister Borrebaeck Chairman
Marianne Olsson Chief Financial Officer
Gunilla Grundström Chief Scientific Officer
Ann Ulrika Gidner Director
Sector and Competitors
1st jan.Capitalization (M$)
SENZAGEN AB10.40%50
EXACT SCIENCES CORPORATION11.40%14 958
GUARDANT HEALTH, INC.27.92%9 958
BGI GENOMICS CO., LTD.106.55%8 452
ADAPTIVE BIOTECHNOLOGIES CORPORATION56.90%6 375
SEEGENE INC--.--%6 306